Ben-Chetrit E, Scherrmann J M, Levy M
Hadassah University Hospital, Jerusalem, Israel.
Arthritis Rheum. 1996 Jul;39(7):1213-7. doi: 10.1002/art.1780390721.
To clarify whether colchicine is excreted in breast milk, and to compare its concentrations in the serum and breast milk of lactating women who have familial Mediterranean fever (FMF).
Using a specific radioimmunoassay, we determined colchicine concentrations in the serum and breast milk of 4 patients at various time points, following oral administration of the drug. The study evaluated 4 patients with FMF who had been taking colchicine on a long-term basis.
Colchicine was found to be excreted in breast milk. Its levels ranged between 1.9 and 8.6 ng/ml, which were similar to those found in the serum (parallel concentration time curves). However, there appeared to be a considerable variation in colchicine milk concentration among the different patients, which might be related to individual breast milk composition and, possibly, to other nutritional or metabolic factors.
The extensive peripheral tissue binding and relatively low concentration of colchicine in breast milk suggests that the amount ingested by the infant is small. Furthermore, based on our clinical experience, nursing appears to be safe for lactating women with FMF who continue to take colchicine.
明确秋水仙碱是否会经母乳排泄,并比较家族性地中海热(FMF)哺乳期妇女血清和母乳中秋水仙碱的浓度。
采用特定的放射免疫分析法,我们在口服药物后的不同时间点测定了4例患者血清和母乳中秋水仙碱的浓度。该研究评估了4例长期服用秋水仙碱的FMF患者。
发现秋水仙碱会经母乳排泄。其水平在1.9至8.6纳克/毫升之间,与血清中的水平相似(浓度-时间曲线平行)。然而,不同患者之间秋水仙碱的乳汁浓度似乎存在相当大的差异,这可能与个体母乳成分有关,也可能与其他营养或代谢因素有关。
秋水仙碱在母乳中广泛与外周组织结合且浓度相对较低,这表明婴儿摄入的量较少。此外,根据我们的临床经验,对于继续服用秋水仙碱的FMF哺乳期妇女,哺乳似乎是安全的。